Strategies for overcoming imatinib resistance in chronic myeloid leukemia. - Wikidata - awgldk - TriplyDB

Strategies for overcoming imatinib resistance in chronic myeloid leukemia.

Strategies for overcoming imatinib resistance in chronic myeloid leukemia.

http://www.wikidata.org/entity/Q37027402

about

PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins.Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.Hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors.Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans.On the stem cell origin of cancer New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells

P2860

Q33618630-05F1AD41-C7E4-4FE3-84F8-9327E5C97483 Q34139691-1F79E423-3140-467F-840C-68FDAE8608B3 Q36741655-4F7A49FB-2039-4592-80DA-81104B454C3D Q36934491-58C1C5EB-CD21-4656-9244-47083FC65051 Q37310478-87B114B1-E61A-4045-9B2B-B0EA0BC499A1 Q37657492-E2C6679A-9D3F-42EB-A062-E705FFF00DD7 Q37692118-4A32D631-D465-4294-858B-4D98245FD68A Q37739713-330F4508-FB98-4403-8548-BF3BC3A3B99C Q45951595-01C6E961-6BC3-4122-AD8B-9A46351DBF06 Q46047569-F237D220-BF45-4746-B9BF-F82A5EE65829 Q58727408-64F8CECB-1C04-4808-A26A-36FB9C43A6C8

P2860

Strategies for overcoming imatinib resistance in chronic myeloid leukemia.

http://www.wikidata.org/entity/Q37027402

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Strategies for overcoming imatinib resistance in chronic myeloid leukemia.

@en

Strategies for overcoming imatinib resistance in chronic myeloid leukemia.

@nl

type

label

Strategies for overcoming imatinib resistance in chronic myeloid leukemia.

@en

Strategies for overcoming imatinib resistance in chronic myeloid leukemia.

@nl

prefLabel

Strategies for overcoming imatinib resistance in chronic myeloid leukemia.

@en

Strategies for overcoming imatinib resistance in chronic myeloid leukemia.

@nl

P1433

Q37027402-5FE13252-B781-4215-A1F8-D6896EC68704

P1476

Q37027402-9CA051D4-7E82-4C57-A88E-9153D3357030

P2093

Q37027402-73C28768-B067-4B84-9A46-425BE08BB13E

Q37027402-EE3EBFD3-EE44-4754-A108-09BA6F6CE77F

P2860

Q37027402-0006D396-3A67-4D03-B3A5-9455A61B4E72

Q37027402-0032FFFC-39AB-40D0-BAB0-CDC56C63F156

Q37027402-020E2D8A-9EDD-4E8B-9B8E-56B5B72D37E8

Q37027402-02786531-D9DB-48B4-8AC5-F5689EDE331B

Q37027402-0A04D427-4AE2-4241-BE5A-FCC420571843

Q37027402-0E76A969-DCC4-4629-ADC9-A6BF64BCC089

Q37027402-121233C4-BBFA-4399-BB84-8785645E00B0

Q37027402-1311AC61-EA47-4E59-B095-90DDBA7331C6

Q37027402-141A2DF8-F7BE-444C-B443-F1F92CDBB663

Q37027402-1A6676A1-B506-41C6-8E45-7EA70872121F

P304

Q37027402-5D65D62B-DCAC-4B92-9397-237AD20DB6F8

P31

Q37027402-1DDAAC72-CA4F-4AF1-94B6-2BC4FB3601F1

P356

Q37027402-F8C0CB6A-FAAD-423F-B95F-494C6E8D7AF3

P433

Q37027402-21E56395-1614-440E-BD4D-D718A6EF0FEB

P478

Q37027402-25542062-5A21-41EA-BC3A-CF144A7ACFB1

P577

Q37027402-2B17C5BF-4382-4516-891D-F0458D610CAD

P698

Q37027402-8A9283DD-DF73-4065-B2E2-D7E64B167372

P921

Q37027402-88617473-C32C-4A10-9375-A0D406231E5A

Q37027402-BC346016-B223-466B-9B29-339D6EF7DCD6

P356

10428190701665988

P1433

Leukemia & Lymphoma

P1476

Strategies for overcoming imatinib resistance in chronic myeloid leukemia.

@en

P2093

Lisa Kujawski

http://www.w3.org/2001/XMLSchema#string

Moshe Talpaz

http://www.w3.org/2001/XMLSchema#string

P2860

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia

Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

P304

2310-2322

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428190701665988

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2007-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18067005

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia